SANTA CLARA, Calif., Dec. 22 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Ihor Gussak, Ph.D., F.A.C.C., NewCardio's Vice President and Chief Medical Officer, will join a distinguished roster of speakers, moderators and panelists at the Center for Business Intelligence (CBI) 4th Annual Cardiac Safety Assessment Summit. The Conference is scheduled for January 12 and 13, 2010, at the Madison A Loews Hotel in Washington, DC. NewCardio is one of the sponsors of the conference, and Dr. Gussak will participate in a panel discussion on the Clinical Validation of Automated ECG Reading Methods.
Dr. Gussak will join Moderator Philip Sager, M.D., Vice President, Clinical Research, Gilead Sciences, Inc. Other participants on the panel include Dr. Borje Darpo, Pharmaceutical Consultant, Dr., Nenad Sarapa, Head of Clinical Pharmacology-Oncology, Hoffmann-La Roche, Inc., and Dr. J. Rick Turner, Senior Director, Cardiovascular Safety, Quintiles ECG Services, on the Clinical Validation of Automated ECG Reading Methods panel to examine the comparison between human readers and automated ECG measurements. The panel will also discuss the evolving approaches to automated QT analyses and their impact on the performance of TQT studies.
Dr. Gussak commented, "I am excited to discuss NewCardio's platform technology and QTinno(TM), our automated cardiac safety solution, at this important and prestigious conference. NewCardio remains committed to improving accuracy and bringing enhanced value to cardiac safety in pharmaceutical development. I am eager to share our latest clinical validation results from blinded studies using QTinno(TM). These results continue to demonstrate that QTinno provides highly accurate results with reduced intrinsic variability and narrower confidence intervals, relative to currently used manual or semi-automated methods."
CBI Research, Inc. is a subsidiary of Advanstar Communications Inc, and dedicated to developing market-driven, unbiased conferences in the fields of pharmaceuticals and biotech, medical devices, risk and insurance and managed care markets. CBI Research, Inc. creates conferences and summits that serve senior executives and government officials by providing a unique platform for highly focused content and presentation. The Cardiac Safety Assessment Summit will provide sessions to discuss how to measure and manage cardiac safety issues such as Arrhythmia, Ischemic Heart Disease, Cardiomyopothy and drugs that effect heart rate and blood pressure. Cardiac safety considerations in Cardiovascular, Oncology, HIV and Diabetes drugs are also explored. More information is available at http://www.cbinet.com/show_conference.cfm?confCode=PC10102&field=summary online.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact: Hayden IR Jeff Stanlis, Partner and VP of Communications (602) 476-1821 email@example.com
SOURCE NewCardio, Inc.
|SOURCE NewCardio, Inc.|
Copyright©2009 PR Newswire.
All rights reserved